Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment InformationMOON SHOTS PROGRAM
Our intentions are noble: put today’s patients at the forefront of our investigation to make their cure a reality. Our process is groundbreaking: use in-house, industry-quality platforms to ensure that our breakthrough discoveries aren’t left sitting in our academic research laboratories.
The B-Cell Lymphoma Moon Shot® is revolutionizing the conventional medical research approach to rapidly adapt pre-clinical findings into patient treatment options and develop personalized therapeutic strategies.
Richard Champlin, M.D.
Professor and Chair, Stem Cell Transplantation and Cellular Therapy
Christopher Flowers, M.D.
Chair, Lymphoma/Myeloma
Michael Wang, M.D.
Professor, Lymphoma/Myeloma
“We should share responsibilities to make scientific progress; it’s a common cause. We need to rally together.“
Watch B-Cell Lymphoma Moon Shot leader Michael Wang, M.D., explain how your gift can help propel research to improve outcomes for lymphoma patients who face the current incurability of their disease.
Treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, according to a Phase I/IIa trial at MD Anderson.
Learn moreLymphoma/Myeloma professor Sattva Neelapu, M.D., shares how the
B-Cell Lymphoma Moon Shot team is working to make the next generation
of Chimeric Antigen Receptor (CAR) T cells therapies more effective
for B-cell lymphoma treatment.
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas
A study at MD Anderson demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein (CREBBP).
